Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
JK Kim, KD Kim, E Lee, JS Lim, HJ Cho… - Cancer …, 2004 - snucm.elsevierpure.com
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
JK Kim, KD Kim, E Lee, JS Lim, HJ Cho, HK Yoon… - Cancer Letters, 2004 - infona.pl
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-kappa B activation in cisplatin-resistant human bladder cancer cell line
E Lee, JK Kim, KD Kim, JS Lim… - CANCER …, 2004 - scholarworks.sookmyung.ac.kr
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
JK Kim, KD Kim, E Lee, JS Lim, HJ Cho… - Cancer …, 2004 - scholars.uthscsa.edu
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line
JK Kim, KD Kim, E Lee, JS Lim, HJ Cho… - Cancer …, 2004 - pubmed.ncbi.nlm.nih.gov
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line.
JK Kim, KD Kim, E Lee, JS Lim, HJ Cho, HK Yoon… - Cancer Letters, 2004 - europepmc.org
The potent anti-cancer agent cis-diamminedichloroplatinum (II)(cisplatin) is currently used
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …
for treating bladder cancer. However, clinical use of this drug for long periods is often limited …